Donor immune cells take on hard-to-treat HPV cancers in early trial
NCT ID NCT04713046
First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 20 times
Summary
This early-phase trial tests whether immune cells from a relative can safely fight advanced HPV16-related cancers that have returned or spread. About 24 patients will receive either a bone marrow transplant or a special infusion of donor T cells. The goal is to see if these treatments are safe and can help control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV 16+ RECURRENT OR METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.